

Supplemental Materials Considered by Thomas A. Baillie, Ph.D., D.Sc.

Case: IPR2015-01835

Patent No. 8,618,135

Doc. No.	Nickname	Description
Paper 30	CFAD Opposition	Petitioner's Opposition To Patent Owner's Contingent Motion To Amend, filed September 7, 2016
1045	Guidance For Industry 2002	Guidance for Industry 2002, Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers (2002)
1046	ICH-E4	ICH-E4, Dose-Response Information to Support Drug Registration (1994)
1047	Reigner	Reigner & Smith Blesch, "Estimating the starting dose for entry into humans: principles and practice," EUR J CLIN PHARMACOL, Vol.57, pp. 835-45 (2002)
1048	Baillie Tr.	Deposition Transcript of Thomas A. Baillie, Ph.D., D.Sc. (August 25, 2016)
1049	Zusman Suppl. Dec.	Supplemental Declaration of Randall J. Zusman, M.D.
1056	Kimball Tr.	Deposition Transcript of S. David Kimball, Ph.D., (July 11, 2016)
1057	Gregg Tr.	Deposition Transcript of Richard Gregg, M.D. (July 26, 2016)

Doc. No.	Nickname	Description
1058	Sacks Tr.	Deposition Transcript of Frank Sacks, M.D. (August 12, 2016)
1059	Rader Tr.	Deposition Transcript of Daniel J. Rader, M.D. (August 23, 2016)
2001	License Agreement	University of Pennsylvania Patent License Agreement (May 19, 2006)
2020	Zusman Tr.	Deposition Transcript of Randall M. Zusman, M.D. (May 19, 2016)
2021	Mayersohn Tr.	Deposition Transcript of Michael Mayersohn, Ph. D. (May 16, 2016)
2024	Baillie Opening Dec.	Declaration of Thomas A. Baillie, Ph.D., D.Sc.
2078	002 Addendum	BMS-201038 Investigator Brochure General Addendum CV145-002, Multiple Dose PO (Oct. 1, 1997)
2079	Rader Approval	Clinical Study Approval (Mar. 20, 2003)
2080	009 Report	Abbreviated Clinical Study Report for CV145-009 (Jan. 7, 2002)
2095	'653 Patent	U.S. Patent No. 6,066,653